⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6751047 | 1.00 | — | — | |
| SCHEMBL28045378 | 1.00 | — | — | |
| SCHEMBL3973719 | 0.94 | — | — | |
| Hydrogen Peroxide SCHEMBL7011640 | 0.94 | — | — | |
| SCHEMBL3973715 | 0.94 | — | — | |
| SCHEMBL4070883 | 0.94 | — | — | |
| SCHEMBL4070880 | 0.94 | — | — | |
| Water SCHEMBL4468314 | 0.94 | — | — | |
| Sulfurous Acid SCHEMBL2184614 | 0.94 | CA1 (0.67) | — | |
| SCHEMBL28329421 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032509-A1 | Testosterone Ester Triglyceride Formulations | ANTARES PHARMA, INC. (US) | 2025-01-30 | — | — | US | claimed |
| US-12144817-B2 | Testosterone ester triglyceride formulations | ANTARES PHARMA, INC. (US) | 2024-11-19 | — | — | US | claimed |
| WO-2022147189-A1 | VARENICLINE PRODRUGS | ANTARES PHARMA, INC. (US) | 2022-07-07 | — | — | WO | claimed |
| US-20220079955-A1 | Testosterone Ester Triglyceride Formulations | ANTARES PHARMA, INC. (US) | 2022-03-17 | — | — | US | claimed |
| US-11123352-B2 | Testosterone ester triglyceride formulations | ANTARES PHARMA, INC. (US) | 2021-09-21 | — | — | US | claimed |
| US-20200289528-A1 | Testosterone Ester Triglyceride Formulations | ANTARES PHARMA, INC. (US) | 2020-09-17 | — | — | US | claimed |
| EP-3675868-A1 | TESTOSTERONE ESTER TRIGLYCERIDE FORMULATIONS | Antares Pharma, Inc. (US) | 2020-07-08 | — | — | EP | claimed |
| US-10646495-B2 | Testosterone ester triglyceride formulations | ANTARES PHARMA, INC. (US) | 2020-05-12 | — | — | US | claimed |
| WO-2019046582-A1 | TESTOSTERONE ESTER TRIGLYCERIDE FORMULATIONS | ANTARES PHARMA, INC. (US) | 2019-03-07 | — | — | WO | claimed |
| US-7198796-B2 | Antifungal parenteral products | VICURON PHARMACEUTICALS INC. (US) | 2007-04-03 | — | — | US | claimed |
| WO-2006085336-A2 | STABILIZED ANTHRACYCLINE GLYCOSIDE PHARMACEUTICAL COMPOSITIONS | DABUR PHARMA LIMITED (IN) | 2006-08-17 | — | — | WO | claimed |
| US-6991800-B2 | Antifungal parenteral products | VICURON PHARMACEUTICALS INC. (US) | 2006-01-31 | — | — | US | claimed |
| US-20050261173-A1 | Antifungal parenteral products | VICURON HOLDINGS LLC | 2005-11-24 | — | — | US | claimed |
| EP-1511378-A2 | ANTIFUNGAL PARENTERAL PRODUCTS | Vicuron Pharmaceuticals, Inc. (US) | 2005-03-09 | — | — | EP | claimed |
| US-20040223997-A1 | Antifungal parenteral products | VICURON HOLDINGS LLC | 2004-11-11 | — | — | US | claimed |
| WO-2003105767-A2 | ANTIFUNGAL PARENTERAL PRODUCTS | VICURON PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | claimed |
| US-20030216418-A1 | Novel compositions comprising trimetrexate and methods of their synthesis and use | MEDIMMUNE ONCOLOGY, INC. | 2003-11-20 | — | — | US | claimed |
| US-20010031755-A1 | Novel compositions comprising trimetrexate | MEDIMMUNE ONCOLOGY, INC. | 2001-10-18 | — | — | US | claimed |
| US-6258821-B1 | TRIMETREXATE ASCORBATE DIHYDROFOLATE REDUCTASE ACTIVITY COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF SUCH TREATMENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOSITION VIRAL INFECTION, FUNGAL INFECTION, YEAST INFECTION, BACTERIA | MEDIMMUNE ONCOLOGY, INC. | 2001-07-10 | — | — | US | claimed |
| WO-2000064447-A1 | NOVEL COMPOSITIONS COMPRISING TRIMETREXATE AND METHODS OF THEIR SYNTHESIS AND USE | MEDIMMUNE ONCOLOGY, INC. (US) | 2000-11-02 | — | — | WO | claimed |